HUMAW
Humacyte IncKey Statistics
About Humacyte Inc
Humacyte Inc. is an innovative biotechnology firm dedicated to developing and commercializing universally implantable human tissues, with a particular emphasis on its groundbreaking human acellular vessel (HAV) technology. The company is at the forefront of transforming vascular and regenerative medicine, leveraging its advanced manufacturing capabilities and robust clinical trial progress to address significant healthcare challenges. Humacyte's strategic focus on improving patient outcomes and its pipeline of transformative tissue-based solutions position it favorably for impactful partnerships and accelerated growth within the regenerative medicine market. By aligning with urgent medical needs, Humacyte is set to make a significant contribution to the future of healthcare.
Fundamentals
| Revenue (TTM) | $2.04M |
| Gross Profit (TTM) | $-76.37M |
| EBITDA | $-100.09M |
| Operating Margin | -6603.00% |
| Return on Equity | -249.80% |
| Return on Assets | -52.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.02 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 248.50% |
| Shares Outstanding | 0 |
| Float | $190.86M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding